LUMO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LUMO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-07), Lumos Pharma's current share price is $2.48. Lumos Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $14.29. Lumos Pharma's Cyclically Adjusted PS Ratio for today is 0.17.
The historical rank and industry rank for Lumos Pharma's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Lumos Pharma's highest Cyclically Adjusted PS Ratio was 2.92. The lowest was 0.16. And the median was 0.55.
LUMO's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Lumos Pharma's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.020. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $14.29 for the trailing ten years ended in Mar. 2024.
The historical data trend for Lumos Pharma's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 0.23 | 0.23 | 0.23 | 0.23 | 0.20 |
For the Biotechnology subindustry, Lumos Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lumos Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Lumos Pharma's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Lumos Pharma's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 2.48 | / | 14.29 | |
= | 0.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Lumos Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.02 | / | 131.7762 | * | 131.7762 | |
= | 0.020 |
Current CPI (Mar. 2024) = 131.7762.
Lumos Pharma Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.068 | 100.560 | 0.089 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 38.167 | 99.070 | 50.767 |
201503 | 11.050 | 99.621 | 14.617 |
201506 | 2.338 | 100.684 | 3.060 |
201509 | 0.264 | 100.392 | 0.347 |
201512 | 10.611 | 99.792 | 14.012 |
201603 | 1.780 | 100.470 | 2.335 |
201606 | 0.627 | 101.688 | 0.813 |
201609 | 0.276 | 101.861 | 0.357 |
201612 | 10.102 | 101.863 | 13.069 |
201703 | 0.851 | 102.862 | 1.090 |
201706 | 3.194 | 103.349 | 4.073 |
201709 | 0.031 | 104.136 | 0.039 |
201712 | 6.935 | 104.011 | 8.786 |
201803 | 2.398 | 105.290 | 3.001 |
201806 | 0.545 | 106.317 | 0.676 |
201809 | 0.029 | 106.507 | 0.036 |
201812 | 0.049 | 105.998 | 0.061 |
201903 | 0.000 | 107.251 | 0.000 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.000 | 108.329 | 0.000 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 0.010 | 108.902 | 0.012 |
202006 | 0.004 | 108.767 | 0.005 |
202009 | 0.009 | 109.815 | 0.011 |
202012 | 0.005 | 109.897 | 0.006 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.001 | 114.631 | 0.001 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.026 | 117.630 | 0.029 |
202203 | 0.013 | 121.301 | 0.014 |
202206 | 0.061 | 125.017 | 0.064 |
202209 | 0.059 | 125.227 | 0.062 |
202212 | 0.061 | 125.222 | 0.064 |
202303 | 0.084 | 127.348 | 0.087 |
202306 | 0.148 | 128.729 | 0.152 |
202309 | 0.001 | 129.860 | 0.001 |
202312 | 0.102 | 129.419 | 0.104 |
202403 | 0.020 | 131.776 | 0.020 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Lumos Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
David B Karpf | officer: Chief Medical Officer | 1360 WILLOW ROAD #100, MENLO PARK CA 94025 |
Aaron Schuchart | officer: Chief Business Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Joseph S Mccracken | director | C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000 |
Richard J Hawkins | director, officer: Chief Executive Officer | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Emmett Cunningham | director | C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134 |
Kevin M. Lalande | director | 201 WEST 5TH STREET, AUSTIN TX 78701 |
John C. Mckew | officer: Chief Scientific Officer | C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756 |
Deerfield Mgmt Iii, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Private Design Fund Iii, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Management Company, L.p. (series C) | 10 percent owner, other: Possible Member of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
Bradley J Powers | officer: Principal Executive Officer | C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010 |
Lori D Lawley | officer: Principal Accounting Officer | C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010 |
Ernest Iii Talarico | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010 |
From GuruFocus
By sperokesalga sperokesalga • 02-15-2023
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 06-21-2023
By Marketwired • 09-14-2023
By Marketwired • 06-28-2023
By PurpleRose PurpleRose • 07-27-2022
By GuruFocusNews GuruFocusNews • 06-15-2022
By Marketwired • 07-26-2023
By Stock market mentor Stock market mentor • 01-03-2023
By sperokesalga sperokesalga • 05-31-2023